Pfizer INC Form 4 insider transactions

Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.

NYSE
Albert Bourla, Chairman & CEO and a Director of Pfizer Inc, purchased 38,000 shares of common stock on August 12, 2026 for $26.34 per share.
NYSE
Jennifer B. Damico, SVP & Controller of Pfizer Inc, sold 3,278 shares of common stock on August 5, 2026 for $25.40 per share.
NYSE
Ronald E Blaylock, a Director of Pfizer Inc, purchased 39,231 shares of common stock on August 5, 2026 for $25.46 per share.
NYSE
Albert Bourla, Chairman & CEO and a Director of Pfizer Inc, received 24 shares of common stock on July 31, 2026.
NYSE
Albert Bourla, Chairman & CEO and a Director of Pfizer Inc, received 24 shares of common stock on July 15, 2026.
NYSE
Albert Bourla, Chairman & CEO and a Director of Pfizer Inc, received 84 shares of common stock on July 9, 2026.
NYSE
Pfizer Chairman & CEO Albert Bourla acquired 25 phantom stock units under a deferred compensation plan on June 30, 2026.
NYSE
Pfizer Inc. director Mortimer J. Buckley has reported transactions involving phantom stock units, settling deferred compensation.
NYSE
Pfizer Inc. Director Joseph Echevarria acquired 1,904.076 phantom stock units on June 26, 2026, as part of a deferred compensation plan.
NYSE
Pfizer Inc. director Shantanu Narayen acquired 2,058.46 phantom stock units, representing deferred compensation.
NYSE
Pfizer Inc. director James C. Smith acquired 1,852.614 phantom stock units, representing deferred compensation, on June 26, 2026.
NYSE
Pfizer Inc. director James Quincey acquired 1,595.307 phantom stock units, representing deferred compensation.
NYSE
Pfizer Inc. director Cyrus Taraporevala reported a transaction involving phantom stock units, settled in common stock.
NYSE
Pfizer Chairman & CEO Albert Bourla acquired 23 phantom stock units under a deferred compensation plan on June 15, 2026.
NYSE
Pfizer's SVP & Controller, Jennifer B. Damico, reported a pre-planned sale of 2,000 shares of common stock scheduled for June 2026.
NYSE
Pfizer Chairman and CEO Albert Bourla acquired 23 phantom stock units through the company's deferred compensation plan.
NYSE
Pfizer Chairman & CEO Albert Bourla acquired 24 phantom stock units under a deferred compensation plan on May 15, 2026.
NYSE
Pfizer Chairman and CEO Albert Bourla has reported transactions involving phantom stock units acquired under a company plan.
NYSE
Pfizer Inc. director Scott Gottlieb was granted 7,686.539 phantom stock units as part of the company's deferred compensation plan for non-employee directors.
NYSE
Pfizer Inc. director Suzanne Nora Johnson acquired 7,686.539 phantom stock units as part of deferred director compensation.
NYSE
Pfizer Inc. director Dan R. Littman was granted 7,686.539 phantom stock units as part of the company's deferred compensation plan.
NYSE
Pfizer Inc. director Ronald E. Blaylock was granted 7,686.539 phantom stock units as part of deferred director compensation.
NYSE
Pfizer Inc. Director Mortimer J. Buckley was granted 7,686.539 phantom stock units as part of deferred director compensation.
NYSE
Pfizer Inc. director Susan Desmond-Hellmann was granted 7,686.539 phantom stock units as part of deferred director compensation.
NYSE
Pfizer Inc. director Joseph Echevarria was granted 7,686.539 phantom stock units as part of deferred director compensation.
NYSE
Pfizer Director Shantanu Narayen acquired 7,686.539 phantom stock units as part of deferred director compensation.
NYSE
Pfizer Inc. director James Quincey was granted 7,686.539 phantom stock units as part of the company's deferred compensation plan for non-employee directors.
NYSE
Pfizer Inc. director James C. Smith was granted 7,686.539 phantom stock units as part of the company's deferred compensation plan for non-employee directors.
NYSE
Pfizer Inc. director Cyrus Taraporevala was granted 7,686.539 phantom stock units as part of the company's deferred compensation plan.
NYSE
Pfizer Chairman and CEO Albert Bourla acquired 22 phantom stock units through the company's deferred compensation plan.